Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-12-18
2007-12-18
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S130100
Reexamination Certificate
active
11198323
ABSTRACT:
Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.
REFERENCES:
patent: 5824307 (1998-10-01), Johnson
patent: WO 99/61065 (1999-12-01), None
Girard et al., A review of vaccine research and development: human acute respiratory infections, 2005, Vaccine, 23:5708-5724.
Huang et al., Recent development of therapeutics for chronic HCV infection, 2006, Antiviral Research, 71:351-362.
Wang et al., Hepatitis E: An Overview and recent advances in vaccine research, 2004, World Journal of Gastroenterology, 10(15):2157-2162.
Alexander et al., Recent advances in diagnosis and therapy of human papillomaviruses, Expert Opinion on Investigational Drugs, Aug. 2000, vol. 9, No. 8, pp. 1753-1765.
Peter Seiler, et al., Induction of Protective Cytotoxic T Cell Responses in the Presence of High Titers of Virus-Neutralizing Antibodies: Implications for Passive and Active Immunization, J. Exp. Med., The Rockefeller University Press, vol. 187, No. 4, 649-654, Feb. 16, 1998.
James E. Crowe, Jr., et al., Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization, Respiratory Viruses Section, Laboratory of Infectious Diseases, Vaccine 1995 vol. 13 No. 9 Dec. 5, 1994.
Riffkin et al. AA single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus@, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al., Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin, Journal of Protein Chemistry, vol. 11, No. 5 (1992) pp. 433-444.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Byers “What Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention?”, CA Journal, vol. 49, No. 6 (Nov./Dec. 1999), pp. 353-361.
Bellone et al., “Cancer immunotherapy: synthetic and natural peptides in the balance”, Immunology Today, vol. 20, No. 19 (1999), pp. 457-462.
Gura, “Systems for Identifying New Drugs Are Often Faulty”, Science, vol. 278 (Nov. 1997), pp. 1041-1042.
Johnson, et al, “A Direct Comparison of the Activities of Two Humanized RSV Monoclonal Antibodies: MEDI-493 & RSHZ19,” The Journal of Infections Diseases, vol. 180, #1, Jul. 1999.
Merck & Co. Inc., Varivax—Varicella Virus Vaccine Live, 2007 product labeling insert, pp. 1-12. Note: originally issued in 1995.
Mahalingam, et al., 1998, “Localization of Varicella-Zoster Virus Gene 21 Protein in Virus-Infected Cells in Culture” J Virol. 72(8):6832-6837.
Merck & Co. Inc., Attenuvax-Measles Virus Vaccine Live, 2006 product labeling insert, pp. 1-9. Note: originally issued in 1990.
Burgoon et al., 1999, “Cloning the Antibody Response in Humans with Inflammatory . . . Antibodies that Recognize Specific Measles Virus Antigens”, J Immunol. 163(6):3496-3502.
Campell Bruce R.
Kinsey Nicole E
MedImmune, Inc.
LandOfFree
Methods of priming the immunogenic activity of vaccines... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of priming the immunogenic activity of vaccines..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of priming the immunogenic activity of vaccines... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858659